Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy
Vernadsky National Library of Ukraine
Переглянути архів Інформація| Поле | Співвідношення | |
| Title |
Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy
|
|
| Creator |
Galbiatti, A.L.S.
Caldas, H.C. Padovani Junior, J.A. Pavarino, E.C. Goloni-Bertollo, E.M. |
|
| Subject |
Short communications
|
|
| Description |
Aim: Methotrexate (MTX) is an antifolate agent that acts inhibiting purine and pyrimidine synthesis. The objective of the study was to evaluate the viability of Hep-2 human laryngeal cancer cells to the treatment with MTX chemotherapy in vitro. Methods: Cultured Hep-2 cells were treated with 0.25, 25.0 and 75 μM MTX for 24 h, and their viability was evaluated with Bcl-2-FITC antibody in flow cytometry. Results: The numbers of viable Hep-2 cells after 24 h treatment with 0.25, 25.0 and 75.0 uM MTX were 85.43%, 22.46% and 8.42%, respectively (p < 0.05). Therefore, MTX possesses a dose-dependent effect on viability of Hep-2 cells in vitro. Conclusion: The highest MTX concentration is associated with highest tumor cell sensitivity of human laryngeal cancer cells of Hep-2 line.
|
|
| Date |
2018-06-21T12:37:44Z
2018-06-21T12:37:44Z 2012 |
|
| Type |
Article
|
|
| Identifier |
Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy / A.L.S. Galbiatti, H.C. Caldas, J.A. Padovani Junior, E.C. Pavarino, E.M. Goloni-Bertollo // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 367-369. — Бібліогр.: 22 назв. — англ.
1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/139856 |
|
| Language |
en
|
|
| Relation |
Experimental Oncology
|
|
| Publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
|
|